What March Biosciences does

March Biosciences is a clinical-stage cell therapy company developing autologous CD5-targeted CAR-T therapies for the treatment of relapsed/refractory T-cell malignancies, including T-cell lymphoma (TCL) and T-cell acute lymphoblastic leukemia (T-ALL). The company was co-founded in 2019 by Sarah Hein, PhD (CEO) and Maksim Mamonkin, PhD (CSO), along with Malcolm Brenner, MD, PhD (Chair, Scientific Advisory Board), with the underlying CD5 CAR technology invented at Baylor College of Medicine. Its lead asset MB-105 is currently advancing through a multicenter Phase 2 trial (NCT06534060) at five US academic centers, following Phase 1 results that demonstrated a 44% overall response rate in r/r T-cell lymphoma and Phase 2 interim data showing a 100% complete response rate in the primary efficacy cohort presented at ASH 2025.

The company's core technology addresses three challenges that have historically limited CAR-T application to T-cell cancers: on-target off-tumor toxicity against normal T-cells, fratricide (self-targeting) during manufacturing, and terminal T-cell differentiation that reduces persistence. MB-105 achieves this through an optimized CD5 CAR design that induces rapid antigen internalization and loss of CD5 on the engineered T cells, eliminating fratricide without requiring gene editing, combined with a proprietary manufacturing process using pharmacological inhibitors that preserve minimally differentiated, highly potent T-cell subsets. Manufacturing scalability is supported by a G-Rex-based process under a development grant from ScaleReady and a partnership with CTMC. MB-105 has received both FDA Orphan Drug Designation (2024) and FDA Regenerative Medicine Advanced Therapy (RMAT) Designation (2025).

Commercially, March Biosciences is pre-revenue. Its business model is the eventual commercialization of approved CAR-T cell therapies, consistent with the $400,000-$500,000+ per-treatment pricing typical of approved CAR-T products. Distribution is currently conducted through academic clinical trial sites via physician referrals. The company is venture-backed with approximately $46.8 million in disclosed funding across equity (Cancer Focus Fund, 4BIO Capital, Mission BioCapital, TMC Venture Fund, Alexandria Venture Investments, Mansueto Investments, among others), non-dilutive grants (CPRIT, ScaleReady), and is headquartered in Houston, Texas.

Name

March Biosciences

Legal name

march.biosciences, Inc.

Website

https://march.bio

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

11–50 employees

Short description

March Biosciences is a clinical-stage cell therapy company developing autologous CD5-targeted CAR-T therapies for patients with relapsed/refractory T-cell lymphoma and T-cell acute lymphoblastic leukemia, with lead asset MB-105 currently in Phase 2 trials.

Ownership category

akta.pro rank

Product category

Cell Therapy / CAR-T Cell Therapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industries

Oncology & Hematology Pharmaceuticals (HLAIAAAC), Rare Oncology & Hematologic Malignancy Therapies (HLAIAIAC)

Keywords

• CAR-T cell therapy
• CD5-targeted therapy
• Hematological cancer treatment
• Autologous cell therapy
• T-cell lymphoma therapy

Headquarters

HQ city

Houston

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure

Revenue model

1. CAR-T Cell Therapy Development and Commercialization: March Biosciences is a clinical-stage biotechnology company developing CAR-T cell therapies for hematological malignancies. The company is advancing MB-105 through Phase 2 clinical trials for relapsed/refractory T-cell lymphoma. Revenue will be generated through eventual commercialization of approved cell therapy products, likely priced at premium levels consistent with other approved CAR-T therapies.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

March Biosciences is a clinical-stage biotechnology company developing autologous CAR-T cell therapies for challenging hematological cancers. Its lead asset, MB-105, is a CD5-targeted CAR-T therapy in Phase 2 trials for relapsed/refractory T-cell lymphoma and T-cell acute lymphoblastic leukemia, using proprietary manufacturing processes and an optimized CAR design that prevents fratricide without complex gene editing.

Product overview

March Biosciences is a clinical-stage cell therapy company developing a portfolio of CAR-T cell therapies targeting challenging hematological cancers. The company's lead asset is MB-105, a CD5-targeted CAR-T therapy for relapsed/refractory T-cell malignancies. The pipeline includes additional programs (MB-107, MB-112, MB-301) at various stages of development. The company's approach combines biological and engineering insights to enable target-unlock without the risk and complexity of additional gene editing, with a streamlined manufacturing process for consistent, robust production of high-quality CAR T-cells.

Differentiator

Problem solved

Functional benefit

Products and services

• MB-105 MB-105 is an autologous CD5-targeted CAR-T cell therapy in clinical development for the treatment of relapsed/refractory T-cell lymphoma (TCL) and T-cell acute lymphoblastic leukemia (T-ALL). It selectively targets CD5, a widely expressed antigen on malignant T-cells, using an optimized CAR design and proprietary manufacturing processes that address on-target off-tumor toxicity and fratricide challenges without complex gene editing. The therapy is being developed for adult and pediatric patients with treatment-resistant T-cell malignancies who have exhausted standard chemotherapy options.

Quantifiable outcome

• 100% complete response rate achieved in primary efficacy cohort of Phase 2 trial for relapsed/refractory T-cell lymphoma
• +2 more outcomes

Named customers5 records

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Four partnerships are on record, tiered core.

• ScaleReadycoreTechnology or Integration · 30 April 2025ScaleReady awarded a $200,000 G-Rex Grant to March Biosciences to support development and manufacturing processes for MB-105 CAR-T cell therapy. The grant aims to enhance scalable cGMP production supporting clinical and commercial development.
• Baylor College of MedicinecoreStrategic or Co-development PartnerMB-105 CD5 CAR T-cell technology was invented at Baylor College of Medicine. Phase 1 clinical trial conducted at BCM continues to enroll T-ALL patients through physician referrals. BCM scientists including Malcolm Brenner and Maksim Mamonkin are co-founders.
• MD Anderson Cancer CentercoreStrategic or Co-development PartnerMD Anderson Cancer Center is a principal investigator site for Phase 2 clinical trial of MB-105. Swaminathan Iyer, MD serves as Principal Investigator. Sits on Scientific Advisory Board.
• CTMCcoreStrategic or Co-development PartnerCell Therapy Manufacturing Center (CTMC) is listed as a partner organization, likely providing manufacturing capabilities and expertise for CAR-T cell therapy production.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Atara Biotherapeutics: Clinical-stage allogeneic T-cell therapy company developing tabelecleucel for EBV-associated lymphomas and other hematological malignancies. Most directly comparable to March as a cell-therapy company focused on rare hematological cancers with regulatory designations and similar commercialization challenges.
• Autolus Therapeutics: Clinical-stage CAR-T company developing obe-cel (Aucatzyl) for B-cell ALL and additional hematological CAR-T programs. Comparable autologous CAR-T platform with a commercial-stage asset, providing a benchmark for development timelines, manufacturing economics, and partnership dynamics in hematological cell therapy.
• Precision BioSciences: Clinical-stage gene editing and cell therapy company developing allogeneic CAR-T candidates for hematological cancers. Comparable in stage, modality (engineered T-cells), and hematological cancer focus, though March uses autologous vs. Precision's allogeneic approach.

Emerging players

• Cabaletta Bio: Clinical-stage cell therapy company developing CAR-T candidates (e.g., CD19-CAR-T) initially for autoimmune diseases with expanding hematological applications. Comparable in CAR-T platform technology and clinical-stage profile, though with a different initial indication focus.
• Fate Therapeutics: Clinical-stage iPSC-derived NK and T-cell therapy company with multiple hematological cancer programs. Comparable in cell-therapy modality and clinical-stage positioning, with a distinct allogeneic platform that competes in the same T-cell malignancy opportunity space.
• Allogene Therapeutics: Clinical-stage allogeneic CAR-T company with multiple hematological cancer programs (CD19, CD70). Comparable modality and target indication space; allogeneic approach could threaten autologous CAR-T economics if commercialized successfully.
• Caribou Biosciences: Clinical-stage allogeneic CAR-T company (CB-010, CB-012) using CRISPR gene editing for hematological cancers. Comparable in cell-therapy modality and clinical-stage positioning with a CRISPR-edited allogeneic platform competing in similar indications.

Broad incumbents

• CRISPR Therapeutics: Commercial-stage gene editing and cell therapy company with Casgevy (exa-cel) approved for sickle cell disease and beta-thalassemia. Comparable cell-therapy modality with broader indication footprint; provides benchmark for gene-edited cell therapy commercialization and platform extension economics.
• Gilead Sciences (Kite): Major oncology company with Kite Pharma cell therapy franchise (Yescarta, Tecartus) — the dominant commercial autologous CAR-T player in B-cell lymphomas. While focused on B-cell rather than T-cell malignancies, it represents the most likely strategic acquirer and sets commercial benchmarks for CAR-T launch dynamics.
• Bristol Myers Squibb: Major oncology company with approved CAR-T products Breyanzi (CD19) and Abecma (BCMA), plus a broad hematology franchise. Sets the bar for CAR-T commercial economics, payer access, and site-network buildout — and is a likely strategic acquirer or partner for emerging hematological CAR-T assets.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/march-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds4 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about March Biosciences